Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis by Masilamani, M. et al.
Rheumatology 2004;43:186–190 doi:10.1093/rheumatology/keg449
Advance Access publication 16 July 2003
Decreased levels of serum soluble complement
receptor-II (CR2/CD21) in patients with
rheumatoid arthritis
M. Masilamani1, J. von Kempis2 and H. Illges1,3
Objective. The soluble cluster of differentiation 21 (sCD21) represents the extracellular portion of the CD21 glycoprotein and is
released by shedding from cell surfaces into plasma. Soluble CD21 binds complement fragments and activates monocytes
through binding to membrane CD23. Elevated levels of sCD21 are found during Epstein–Barr virus EBV infections, B-cell
lymphoma and other lymphoblastoid tumours. The present study was undertaken to investigate levels of sCD21 in rheumatoid
arthritis.
Methods. A speciﬁc enzyme-linked immunoassay was developed using sCD21, biochemically puriﬁed to homogeneity from
human plasma as a standard for the determination of sCD21 concentration in patient sera. Peripheral blood B and T
lymphocytes were isolated from healthy donors and rheumatoid arthritis patients and cultured, and supernatants were analysed
for CD21 shedding.
Results. The normal values of serum sCD21 in healthy individuals between 20 and 40 yr of age ranged from 100 to 477 ng/ml
(median 292 ng/ml), decreasing with age but not differing with gender. In rheumatoid arthritis patients, sCD21 levels ranged
from 50 to 300 ng/ml (median 182 ng/ml), did not differ with age and were independent of rheumatoid factor.
Conclusions. In contrast to healthy donors, patients with rheumatoid arthritis have signiﬁcantly lower sCD21 levels
(P<0.0001), independently of the age of the patients. Sorted B cells from rheumatoid arthritis patients released amounts of
CD21 comparable with those of normal controls. Possible causes and consequences of the ﬁndings are discussed.
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Rheumatoid arthritis (RA) is a systemic chronic inﬂammatory
disease that predominantly affects the joints. Diagnosis is based on
symptoms related to synovial inﬂammation, the presence of
rheumatoid factor (RF) and radiological signs of joint damage
[1]. The aetiology of RA is still unknown. In the extremely complex
pathophysiology, innate immunity may play an important role
[2]. RF has been established as a useful serological marker for
diagnosis, and a variety of other serum parameters, e.g. acute-
phase proteins such as C-reactive protein and ﬁbrinogen, indicate
disease activity. Recently, a combination of RF and antibodies
to cyclic citrullinated peptide was reported as a possible diag-
nostic tool to differentiate between RA and undifferentiated poly-
arthritis [3]. Markers of increased connective tissue turnover and
certain soluble membrane-bound proteins, such as soluble
interleukin (IL)-2 receptor, soluble CD4, IL-6, -1-antitrypsin
and complement activation products, are elevated in RA [4].
Complement receptor II (CD21) is the receptor for C3d
fragments on immune complexes and Epstein–Barr virus (EBV).
In B lymphocytes, CD21 ampliﬁes the signal through the B-cell
receptor [5]. CD21 is shed from the surface of the cell and is found
circulating in plasma. The clinical signiﬁcance of sCD21 is shown
by higher levels in sera of patients with certain B lymphomas, EBV
infection and other lymphoblastoid tumors [6]. Soluble CD21
activates monocytes through binding to membrane CD23. As
sCD21 could potentially bind to its ligands in plasma, the amount
of sCD21 in circulation could be a modulator of immunity [7].
We have previously shown a reduction of surface CD21 in
synovial lymphocytes compared with peripheral blood lympho-
cytes and activated T cells [8, 9] and have recently reported the
isolation and characterization of sCD21 from human plasma [10].
Here we investigated if and to what extent sCD21 levels might be
inﬂuenced by autoimmune RA. Using puriﬁed sCD21 from human
plasma as standard, we established an enzyme-linked immunosor-
bent assay (ELISA) for the quantiﬁcation of sCD21 in serum. Our
data demonstrate that levels of sCD21 in healthy individuals
decrease with age, independently of gender (n¼ 235). In sera of
patients with RA (n¼ 220), sCD21 was signiﬁcantly reduced
(P<0.0001). The reduction of sCD21 observed in RA is indepen-
dent of both age and the presence of RF. Studying isolated
lymphocytes, we determined that shedding of the sCD21 protein
from RA B lymphocytes is not impaired.
Materials and methods
Human serum, cells, antibodies and reagents
Human serum was collected from healthy blood donors and
patients with RA, diagnosed according to the American College of
Rheumatology classiﬁcation criteria [1]. In all instances patients
gave informed consent. The monoclonal anti-CD21 antibodies
BU32 [immunoglobulin (Ig) G1] and THB5 (IgG2a) were grown in
serum-free hybridoma medium (Invitrogen, Karlsruhe, Germany)
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at 37C in 7.5% CO2 and puriﬁed by afﬁnity chromatography
with protein G Sepharose (Amersham, Freiburg, Germany).
Biotinylated BU32 was purchased from Chemikon (Hofheim,
Germany).
Puriﬁcation of soluble CD21
Soluble CD21 from human plasma was puriﬁed to homogeneity by
afﬁnity chromatography and density gradient centrifugation as
described before [10]. Using puriﬁed sCD21 as standard, we
developed a sandwich ELISA for the determination of sCD21 in
the sera of healthy and diseased individuals.
Quantiﬁcation of soluble CD21 from human
serum by ELISA
A sandwich ELISA was performed to measure sCD21 levels
in human serum. The monoclonal antibodies THB5 and biotinyl-
ated BU32 were used as capture antibody and revealing antibody
respectively. Titration was performed with puriﬁed sCD21 [10] and
a standard curve was plotted. Brieﬂy, THB5 was coated onto an
ELISA plate (TPP, Trassadingen, Switzerland) at a concentration
of 5g/ml in coating buffer (0.1 M Na2HPO4/NaH2PO4, pH 9.0)
for 12–15 h at 4C. After two washes with phosphate-buffered
saline containing 0.1% Tween 20 (PBST), the plate was blocked
with 1% milk powder in PBST for 2 h. The serum samples at
appropriate dilutions were added to the plates along with the
standard in triplicates. The plates were incubated at 4C for
12–15 h, washed twice with PBST and then incubated for 2 h with
BU32-biotin. After two washes, streptavidin coupled to horse-
radish peroxidase was added and H2O2 /o-phenylenediamine as
substrate/colouring agent. The enzyme reaction was quantiﬁed by
taking the optical density at 492 nm in an ELISA reader (Anthos
Microsystem, Krefeld, Germany) and sCD21 concentrations were
calculated by extrapolating from the standard graph.
Isolation, sorting and culture of peripheral
blood lymphocytes
Lymphocytes were puriﬁed by Ficoll density gradient centrifuga-
tion of fresh human blood. B and T cells were enriched by magnetic
sorting as previously described [9]. The relative purity of the cells
was determined by cytometric analysis using anti-CD4-PE/anti-
CD8-FITC as markers for T cells and anti-CD19-PE/anti-CD21-
FITC as markers for B cells. Cells were stained in microtitre plates
and loaded into a FACScan (Becton Dickinson, Heidelberg,
Germany) using a self-constructed loader as previously described
[11]. B and T cells (1 107 per ml) were cultured for 36 h in Iscove’s
DMEM medium (Invitrogen) supplemented with 10% fetal
calf serum, 1000U/ml penicillin and 100g/ml streptomycin at
37C in 7.5% CO2. Soluble CD21 concentrations in cell culture
supernatants were then analysed by ELISA.
Statistics
Statistical calculations and graphical illustrations were performed
using Instat/Prism software. The Kruskal–Wallis test was used
for non-parametric analysis of variance (ANOVA) and the
Mann–Whitney test to obtain non-parametric two-tail P values.
Results
Serum soluble CD21 levels in healthy volunteers
We analysed sCD21 levels in sera of 235 healthy volunteers of
different ages. Soluble CD21 concentration was highest between 1
and 20 yr of age and was signiﬁcantly lower in older individuals
(P<0.0001). The normal range of sCD21 in healthy individuals
20–40 yr of age was 100–477 ng/ml with a median of 292 ng/ml
(Fig. 1A). The median values of sCD21 of other age groups
were as follows: 1–20 yr, 340 ng/ml; 40–60 yr, 222 ng/ml; 60–80 yr,
209 ng/ml; 80 yr, 195 ng/ml. While the serum levels of sCD21
were not signiﬁcantly different between genders (Fig. 1B), an
age-dependent decrease was found in both male and female control
groups, with high signiﬁcance using the non-parametric ANOVA
(P¼ 0.002 for males and 0.005 for females; data not shown).
Serum soluble CD21 concentrations in RA
Serum samples of 220 conﬁrmed RA patients were tested for
sCD21 concentrations by ELISA and compared with those of
controls (Fig. 2A). The sCD21 concentrations were found to be
signiﬁcantly lower in RA patients than in normal controls: from 50
to 300 ng/ml (median 182 ng/ml). In order to make sure that the
observed reduction in sCD21 levels was not due to old age of the
patients, we compared sCD21 concentrations in RA with those in
age-matched normal controls (Fig. 2A), revealing a statistically
highly signiﬁcant reduction (P<0.0001). Unlike sCD21 concen-
trations of controls, those of RA patients showed no statistically
signiﬁcant reduction with age (P¼ 0.0732, data not shown). We
thus conclude that the reduction in serum sCD21 is associated with
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FIG. 1. Serum soluble CD21 concentration decreases with age
and is independent of gender. Sera were obtained from healthy
volunteers and tested for sCD21 concentration by ELISA (see
Materials and methods). The data are grouped according to age
in panel A and sex in panel B. Sample numbers in panel A were
as follows: &, 1–20 yr, n¼ 11; ~, 20–40 yr, n¼ 143; !, 40–60 yr,
n¼ 38; ^, 60–80 yr, n¼ 32; *, 80þ yr, n¼ 11. Sample numbers
in panel B were as follows: &, females, n¼ 76; ~, males, n¼ 84.
Kruskal–Wallis test for non-parametric ANOVA was performed
to derive the statistical signiﬁcances. For variation with age and
gender, P<0.0001 and P¼ 0.3014 respectively.
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the disease itself and not only leads to lower levels of sCD21 but
also eliminates differences between age groups. We were further
interested to know if the presence of RF correlates to sCD21 levels.
Comparison of sCD21 concentrations of RFþ and RF patients
did not demonstrate signiﬁcant differences between the two groups
(P¼ 0.6336) (Fig. 2C).
B lymphocytes from RA patients and controls
shed similar amounts of CD21
Because RA is characterized by autoimmune reactions, lympho-
cyte proliferation and complement activation, we presumed that
the reduction in sCD21 could be due to defective shedding of CD21
from lymphocytes. To test this hypothesis we isolated peripheral
blood lymphocytes from two healthy individuals and two RA
patients and sorted B and T lymphocytes for further culture. The
purity of sorted lymphocytes was tested by cytometric analysis
(Fig. 3A and B). Supernatants were collected after 36 h of
incubation and tested for sCD21 by ELISA (Fig. 3C). B cells
from controls and RA patients shed similar amounts of CD21 into
the supernatant. T cells from the control and RA patients shed very
little or undetectable amounts of CD21 molecules. We therefore
conclude that the shedding of CD21 protein by peripheral B cells is
normal in RA and shedding by T cells is at least not elevated to
the extent of yielding detectable amounts of sCD21.
Discussion
The activation of different parts of the complement cascade in RA
has been known for a long time [5, 12]. One ﬁnding among many
showed that levels of the CD21 ligand C3d are elevated in RA
synovial ﬂuids [13]. The study presented here demonstrates that the
levels of sCD21 in the sera of RA patients were signiﬁcantly lower
than in a control group of age-matched healthy individuals. In
addition, we examined a small heterogeneous group of patients
with other autoimmune diseases (n¼ 17) in whom the serum levels
of sCD21 appeared to be comparable to those of the control group
of healthy individuals (data not shown). However, because in this
heterogeneous group of diseases the number of cases for each
disease was low, we cannot conclude that the reduction in sCD21
is speciﬁc for RA. It may well be a feature in the pathogenesis of
other autoimmune or inﬂammatory diseases.
Our data indicate that the reduction of sCD21 levels is not due to
the age of the patients or related to the presence of RF. There are
several possible reasons for this reduction. First, an increased
amount of complement activation products (e.g. C3d) could
bind to sCD21, leading to increased clearance from plasma.
Other immune complex-associated autoimmune disorders show no
association with sCD21 levels, suggesting that classical immune
complexes might not be involved in this process. However, in
RA patients the turnover of C3 (which is about 1 g/l in healthy
human sera) might be slightly elevated compared with other
diseases. Comparing the amounts of C3 and sCD21 in sera, a
small percentage of converted C3 would readily be sufﬁcient
to ‘neutralize’ sCD21. Secondly, the elevated concentrations of
protease inhibitors, such as -1-antitrypsin, could prevent shedding
of CD21 from the lymphocyte surface by inhibiting unknown
proteases [14]. Thirdly, the release of sCD21 from cells other than
lymphocytes or lymphocytes outside the peripheral blood might be
impaired during RA.
In RA patients the switched memory B-cell pool is enlarged and
CD38þ plasma-cell-like B cells are present in higher numbers [15].
However, the reduction in sCD21 cannot be attributed to
peripheral blood B cells alone because peripheral blood B cells
from RA patients were shown to produce the same low amounts as
those from healthy individuals. This ﬁnding suggests that the
majority of sCD21 is produced by other cell types or by B cells in
different locations, for example in the spleen.
Activation of B cells through either the B-cell receptor or
through C3d opsonized immune complexes decreases the density of
CD21 on the surface of B cells [16]. Therefore, the decrease in
sCD21 levels in plasmamay be caused either by activation of B cells
(as seen in synovial lymphocytes [8]) or by increased clearance of
plasma sCD21 through circulating C3d opsonized immune com-
plexes. Raji B-cells activated by mitogen shed more CD21, in
addition to a decrease in surface levels (M.Masilamani,D.Kassahn
and H. Illges, unpublished observation), suggesting that the
decrease in sCD21 in RA is mainly due to increased clearance of
sCD21 through immune complexes. The activated complement
fragments in RA may be sufﬁciently elevated to neutralize the
increased shedding of CD21 from activated B cells.
FIG. 2. Serum soluble CD21 concentration is signiﬁcantly
reduced in RA independently of the presence of RF. Soluble
CD21 concentrations were measured by ELISA from conﬁrmed
RA patients and compared with those of healthy controls. The
controls are the same individuals as shown in Fig. 1 and their
data are used again here for comparison. (A) Age independence
of sCD21 levels in RA patients. Age of RA patients (open
symbols, &, 21–40 yr, !, 41–60 yr, *, 61–80 yr) compared with
the corresponding age group of healthy controls (solid symbols,
&, !, *). P<0.0001. (B) RA, ~ (n¼ 220) compared with
controls, & (n¼ 235). P<0.0001 for the comparison between
control and RA subjects. (C) Comparison of RFþ (~, n¼ 113)
with RF (!, n¼ 46) RA patients (P¼ 0.6336).
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FIG. 3. RA and healthy control lymphocytes shed similar amounts of CD21. Peripheral blood lymphocytes from two healthy controls
and two RA patients were obtained under sterile conditions. B and T lymphocytes (107 per ml) were sorted negatively by magnetic
activated cell sorting using CD3 and CD19 magnetic beads respectively and cultured for 36 h. The purity of sorting from each sample
of control B and T cells (A, upper and lower panels) and RA B cells and T cells (B, upper and lower panels) was determined by FACS
analysis. Soluble CD21 concentration was estimated in the cell culture supernatants. (C) Amounts of CD21 shed from B and T cells
from controls (1 and 2) and RA patients (3 and 4).
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In conclusion, the reduction in sCD21 serum level seen in RA
underlines the importance of the innate immune system in
autoimmune reactions and possibly in the pathogenesis of RA.
Experiments using tissues from patients and healthy donors are
under way to analyse the mechanisms leading to the reduction in
sCD21 in the peripheral blood of RA patients.
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